Samsung, SK and Daewoong Aiming at US$200mn Sales in the U.S.
Samsung Bioepis's biosimilar Renflexis, SK Biopharmaceuticals' epilepsy drug Xcopri, and Daewoong Pharmaceutical's botulinum toxin Nabota, are expected to exceed US$200 million in U.S. sales this year.
The Renflexis sales added up to US$196 million last year. According to industry sources, the biosimilar is based on Janssen’s Remicade for autoimmune disorder treatment, the Remicade biosimilar market has been very stable for years, and the share of Samsung Bioepis in the market has risen gradually.
Kyobo Securities, in the meantime, recently said that the U.S. sales of the epilepsy drug would be somewhere between US$205 million and US$228 million this year, up 57 to 75 percent year on year. The drug of SK Biopharmaceuticals was approved by the U.S. FDA in 2019 and the sales topped US$126.7 million in 2022.
Last year, the sales of Daewoong's Nabota in North America, which is sold under the name of Jeuveau, increased 49 percent to US$148.6 million. Local marketing partner Evolus recently estimated this year’s sales at US$180 million or more.
Hanmi Pharmaceutical’s Rolontis, Hadlima of Samsung Bioepis, and Celltrion’s Yuflyma are forecast to top US$100 million in U.S. sales this year. The first for neutropenia patients was released in October 2022 and reached US$10 million in less than three months. Hadlima and Yuflyma are Humira-based biosimilars and will be launched in the U.S. market on July 1.